Viruses related to deadly human diseases found in Chinese bats
The discovery of 20 previously unknown viruses might be a cause for concern. PHOTO ILLUSTRATION: PIXABAY
Scientists have discovered 20 previously unknown viruses in bats from China's Yunnan province, including two closely related to the deadly Nipah and Hendra viruses, raising fresh concerns about the risk of animal pathogens infecting people.
The viruses related to Nipah and Hendra came from fruit bats caught near orchards close to villages, places where people and farm animals are more likely to come into contact with wildlife.
The findings, published on June 24 in the journal PLOS Pathogens, underscore how much remains unknown about the microbes carried by bats – animals that serve as natural hosts for some of the world's most dangerous pathogens.
Scientists have long warned that climate change, farming expansion, and urbanisation are bringing animals and people into closer contact, increasing the likelihood of new viruses emerging and sparking outbreaks, as seen with Sars , Ebola, and Covid-19.
'This study highlights that we know very little about the viruses that infect bats and those that exist in our world more generally,' said Dr Tim Mahony, director of the Centre for Animal Science at Australia's University of Queensland, who was not part of the study.
The research involved scientists from China and the University of Sydney, who examined the kidneys of 142 bats collected over four years in Yunnan.
They identified 22 viruses in total, 20 of which had not been previously recorded. Among them were two henipaviruses closely related to Nipah and Hendra, which can cause fatal brain inflammation and respiratory illness in people, with mortality rates as high as 75 per cent .
The team also reported two new bacterial species and one previously unknown parasite.
While most studies of bat viruses focus on faeces , the researchers looked at kidney tissue, which plays a role in virus shedding through urine – a lesser-studied but potentially important route of transmission.
The two new henipaviruses were found in fruit bats living near agricultural areas, where urine from bats may contaminate fruit that is eaten by people or livestock.
The findings 'underscore critical zoonotic threats', the study authors wrote, adding that the potential for such viruses to infect humans or farm animals needs urgent attention.
Despite the potential implications, one of the study's corresponding authors declined to speak in detail, telling Bloomberg by e-mail that 'the topic is quite sensitive' due to how politically charged it has become.
Experts say the discovery is scientifically significant, though it is still too early to know how dangerous the new viruses might be.
'This discovery basically further confirms the diversity of bat viruses in general and henipaviruses in particular,' said Professor Linfa Wang at the Programme in Emerging Infectious Diseases at Duke-NUS Medical School. 'My overall assessment is that we need to watch closely, but not be overly concerned at the present time.' BLOOMBERG
Join ST's Telegram channel and get the latest breaking news delivered to you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
12 hours ago
- Straits Times
Viruses related to deadly human diseases found in Chinese bats
The discovery of 20 previously unknown viruses might be a cause for concern. PHOTO ILLUSTRATION: PIXABAY Scientists have discovered 20 previously unknown viruses in bats from China's Yunnan province, including two closely related to the deadly Nipah and Hendra viruses, raising fresh concerns about the risk of animal pathogens infecting people. The viruses related to Nipah and Hendra came from fruit bats caught near orchards close to villages, places where people and farm animals are more likely to come into contact with wildlife. The findings, published on June 24 in the journal PLOS Pathogens, underscore how much remains unknown about the microbes carried by bats – animals that serve as natural hosts for some of the world's most dangerous pathogens. Scientists have long warned that climate change, farming expansion, and urbanisation are bringing animals and people into closer contact, increasing the likelihood of new viruses emerging and sparking outbreaks, as seen with Sars , Ebola, and Covid-19. 'This study highlights that we know very little about the viruses that infect bats and those that exist in our world more generally,' said Dr Tim Mahony, director of the Centre for Animal Science at Australia's University of Queensland, who was not part of the study. The research involved scientists from China and the University of Sydney, who examined the kidneys of 142 bats collected over four years in Yunnan. They identified 22 viruses in total, 20 of which had not been previously recorded. Among them were two henipaviruses closely related to Nipah and Hendra, which can cause fatal brain inflammation and respiratory illness in people, with mortality rates as high as 75 per cent . The team also reported two new bacterial species and one previously unknown parasite. While most studies of bat viruses focus on faeces , the researchers looked at kidney tissue, which plays a role in virus shedding through urine – a lesser-studied but potentially important route of transmission. The two new henipaviruses were found in fruit bats living near agricultural areas, where urine from bats may contaminate fruit that is eaten by people or livestock. The findings 'underscore critical zoonotic threats', the study authors wrote, adding that the potential for such viruses to infect humans or farm animals needs urgent attention. Despite the potential implications, one of the study's corresponding authors declined to speak in detail, telling Bloomberg by e-mail that 'the topic is quite sensitive' due to how politically charged it has become. Experts say the discovery is scientifically significant, though it is still too early to know how dangerous the new viruses might be. 'This discovery basically further confirms the diversity of bat viruses in general and henipaviruses in particular,' said Professor Linfa Wang at the Programme in Emerging Infectious Diseases at Duke-NUS Medical School. 'My overall assessment is that we need to watch closely, but not be overly concerned at the present time.' BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Times
18 hours ago
- Business Times
Viruses related to deadly human diseases found in Chinese bats
[SINGAPORE] Scientists have discovered 20 previously unknown viruses in bats from China's Yunnan province, including two closely related to the deadly Nipah and Hendra viruses, raising fresh concerns about the risk of animal pathogens infecting people. The viruses related to Nipah and Hendra came from fruit bats caught near orchards close to villages, places where people and farm animals are more likely to come into contact with wildlife. The findings, published on Tuesday (Jun 24) in the journal Plos Pathogens, underscore how much remains unknown about the microbes carried by bats – animals that serve as natural hosts for some of the world's most dangerous pathogens. Scientists have long warned that climate change, farming expansion, and urbanisation are bringing animals and people into closer contact, increasing the likelihood of new viruses emerging and sparking outbreaks, as seen with Sars, Ebola, and Covid-19. 'This study highlights that we know very little about the viruses that infect bats and those that exist in our world more generally,' said Tim Mahony, director of the Centre for Animal Science at Australia's University of Queensland, who was not part of the study. The research involved scientists from China and the University of Sydney, who examined the kidneys of 142 bats collected over four years in Yunnan. They identified 22 viruses in total, 20 of which had not been previously recorded. Among them were two henipaviruses closely related to Nipah and Hendra, which can cause fatal brain inflammation and respiratory illness in people, with mortality rates as high as 75 per cent. A NEWSLETTER FOR YOU Friday, 2 pm Lifestyle Our picks of the latest dining, travel and leisure options to treat yourself. Sign Up Sign Up The team also reported two new bacterial species and one previously unknown parasite. While most studies of bat viruses focus on feces, the researchers looked at kidney tissue, which plays a role in virus shedding through urine, a lesser-studied but potentially important route of transmission. The two new henipaviruses were found in fruit bats living near agricultural areas, where urine from bats may contaminate fruit that's eaten by people or livestock. The findings 'underscore critical zoonotic threats', the study authors wrote, adding that the potential for such viruses to infect humans or farm animals needs urgent attention. Despite the potential implications, one of the study's corresponding authors declined to speak in detail, telling Bloomberg by e-mail that 'the topic is quite sensitive' due to how politically charged it has become. Experts say the discovery is scientifically significant, though it's still too early to know how dangerous the new viruses might be. 'This discovery basically further confirms the diversity of bat viruses in general and henipaviruses in particular,' said Linfa Wang, professor at the Programme in Emerging Infectious Diseases at Duke-NUS Medical School. 'My overall assessment is that we need to watch closely, but not be overly concerned at the present time.' BLOOMBERG
Straits Times
3 days ago
- Straits Times
Novo Nordisk obesity shot tied to greater weight loss at lower doses
Novo built its next-generation obesity portfolio on CagriSema, which combines its existing blockbuster shot Wegovy with a second, newer medicine. PHOTO: PIXABAY Novo Nordisk A/S's next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about three-quarters of the patients ever making it to the highest dose. Surprisingly, patients who chose to stick with a lower dose lost more weight on average. The studies allowed patients to stop at lower doses of the drug, an unusual option in a trial. Researchers presenting new data on June 22 at the American Diabetes Association (ADA) meeting in Chicago say the findings offer clues as to how the drug would be used in real life. There's a group of people who respond very well to this medicine, said Dr Timothy Garvey, director of the Diabetes Research Center at the University of Alabama at Birmingham, who helped lead the trials. 'Some patients can be really effectively treated' without hitting the highest dose, Dr Garvey said in an interview. Investigators were allowed to keep people on lower doses to manage side effects or if they were already losing enough weight. It's unclear why some patients did better, though Dr Garvey noted that they tended to have lower body-mass index at the start of the trial. 'We need to study that a little more,' he said. Novo built its next-generation obesity portfolio on CagriSema, which combines its existing blockbuster shot Wegovy with a second, newer medicine. The one-two punch has so far failed to deliver as much weight loss as Novo predicted, taking a toll on the drugmaker's stock price. In a study released in December 2024 , obese patients lost 20.4 per cent of their weight on CagriSema, short of the company's oft-touted goal at least 25 per cent weight loss. A second study in March 2025 on diabetes also failed to deliver as much weight loss as investors had anticipated. Novo is now presenting full data from both trials as it tries to persuade doctors and investors that the drug can be a contender in the competitive market. Dr Enrique Caballero, president-elect of medicine and science for the ADA, said the studies showed 'very compelling data' for CagriSema. 'It's a very meaningful weight reduction,' Dr Caballero, who is also director of international innovation programs at Harvard Medical School, said in an interview. 'In competition with the other molecules that are available, that's really in the ballpark figure of what we are seeing now.' Novo plans to seek regulatory approval for CagriSema early next year, and it's still running a range of large studies to determine just how much the drug can help patients. The latest big trial, begun in June 2025 , will be longer than the initial studies to capture more potential weight loss, said Dr Martin Holst Lange, Novo's drug development chief. The company is also testing CagriSema head-to-head with Eli Lilly & Co.'s Zepbound, the obesity drug that's currently winning the majority of new prescriptions in the US. Among important data being presented this weekend are CagriSema's safety results, which show the drug cocktail has similar side effects to Wegovy despite delivering more weight loss, Dr Lange said. About 6 per cent of obesity patients and 8.4 per cent of diabetes patients quit the trials due to side effects, dropout rates that Novo said are low. The drugmaker is also looking to carve out a niche with its drug's heart benefit. Wegovy is approved to prevent strokes and heart attacks, and Novo is running a large trial to see whether CagriSema can also lead to better outcomes for people with both obesity and heart disease. Novo is also planning a separate large study of the experimental drug that's mixed with Wegovy to make CagriSema. Called cagrilintide, it mimics a gut hormone called amylin, rather than the GLP-1 hormone that's the basis for Wegovy and Zepbound. A cagrilintide-only group in the obesity study presented at the ADA meeting lost an average of 11.5 per cent of their body weight. Novo hopes that could create a new market. 'Obviously we need to have the potential for big weight loss for patients who need that, but there will also be patients who need a moderate weight loss,' Dr Lange said. BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.
